Davila, ICampo, PCimbollek, SAlmonacid-Sanchez, CQuirce, SMoreira, ARamirez, ASoto-Campos, G2023-05-032023-05-032021-07-05Dávila I, Campo P, Cimbollek S, Almonacid Sánchez C, Quirce S, Moreira A, et al. Cluster Subanalysis of Patients With Severe Asthma Who Responded to Omalizumab. J Investig Allergol Clin Immunol. 2022 Jun 20;32(3):213-2151018-9068http://hdl.handle.net/10668/21740Asthma is a heterogeneous disease that manifests with variations in signs and symptoms, age of onset, triggers, disease progression, pulmonary function, and airway inflammation [1]. Recently, significant efforts have been made to phenotype asthma, with the objective of identifying patients who are responsive to specific therapies [2]. The different methods used to phenotype asthma have generated bias [3]. In this sense, cluster approaches are one of the most frequently used unbiased techniques [4]. They are generally based on cohorts of patients analyzed using a cluster methodology, which gives rise to various phenotypes [5-7]. Here, we used an innovative contrasting approach, namely, a real-world study in which we selected patients with an excellent response to omalizumab (hyperresponders) and performed a cluster analysis to identify responder phenotypes.enAllergens and epitopesAsthmaEosinophilsIgEAnti-Asthmatic AgentsAsthmaHumansOmalizumabresearch article34581281Restricted AccessAsmaProgresión de la EnfermedadAnálisis por ConglomeradosInflamaciónOmalizumab10.18176/jiaci.0731http://www.jiaci.org/revistas/doi10.1876_jiaci.0731_material-suppl.pdf